Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639385 | 1.00 | CA1 (0.34) | CA1CA2HCRTR2KDM4EALDH1A1 | |
| SCHEMBL6135269 | 1.00 | CA1 (0.34) | CA1CA2HCRTR2KDM4EALDH1A1 | |
| SCHEMBL4334769 | 0.89 | CA1 (0.40) | CA1CA2ALDH1A1USP2TSHR | |
| SCHEMBL2099337 | 0.89 | — | — | |
| SCHEMBL18604421 | 0.87 | — | — | |
| SCHEMBL2589380 | 0.86 | CYP19A1 (0.33) | — | |
| SCHEMBL25937220 | 0.86 | CYP19A1 (0.33) | — | |
| SCHEMBL1606337 | 0.82 | CA1 (0.36) | CA1CA2 | |
| SCHEMBL30055490 | 0.82 | CA1 (0.36) | CA1CA2USP2TSHRHRH3 | |
| SCHEMBL24511672 | 0.80 | CA1 (0.34) | CA1CA2USP2TSHRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448377-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-21 | — | — | US | disclosed |
| EP-4066893-B1 | 6,7,8,9-TETRAHYDRO-4H-QUINOLIZIN-4-ONE COMPOUND AS OREXIN TYPE 2 RECEPTOR AGONIST | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20230037557-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4066893-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-10-05 | — | — | EP | disclosed |
| EP-2879673-B1 | 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders | BIOGEN MA INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10017506-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017506-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2877185-B1 | 2-(1-(1-(6-((CYCLOHEXYL)OXY)-5-(TRIFLUOROMETHYL)NAPHTHALEN-2-YL)ETHYL)PIPERIDIN-3-YL)ACETIC ACID DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATIONS AND AUTOIMMUNE DISORDERS | BIOGEN MA INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9944666-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20110065928-A1 | Process for Preparing Azabicyclic Compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2010015524-A1 | METHOD FOR STEREOSELECTIVE SYNTHESIS OF BICYCLIC HETEROCYCLENE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CA1 2356/4885CA2 1899/4885HCRTR2 4377/4885 |
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | CA1 2968/4885CA2 3263/4885HCRTR2 2280/4885 |
| US-12448377-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | CA1 1114/4885CA2 600/4885HCRTR2 1/4885 |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | CA1 1819/4885CA2 1760/4885HCRTR2 4292/4885 |
| US-20110065928-A1 | Process for Preparing Azabicyclic Compounds | AZI2, DHPS, PAICS | CA1 1907/4885CA2 3276/4885HCRTR2 4809/4885 |
| US-10017506-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | CA1 2758/4885CA2 3904/4885HCRTR2 2800/4885 |
| US-20230037557-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | CA1 1114/4885CA2 600/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.